International
The Morning Science

What science found today

‹
 

Research

Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH

Nature · By Chelsea L. Thorsheim ·

The Brief

  • A Nature Communications study reports a pathway in which selective, non-canonical mTOR signaling via FLCN regulates VLDL assembly and secretion.
  • The pathway involves TFE3-dependent VLDL-triglyceride secretion from the liver.
  • The authors report that targeting this pathway efficiently suppresses liver steatosis (fatty liver) and protects against MAFLD/MASH.

Why it matters

It identifies a mechanism linking mTOR signaling to hepatic lipid export, a potential target for fatty liver disease (MAFLD) and its progression to MASH.

Who’s affected

  • biomedical researchers studying liver metabolism and fatty liver disease
  • clinicians and drug developers interested in MASH therapeutics

Nature Communications, Published online: 18 November 2026; doi:10.1038/s41467-026-79397-6 The study identified a pathway that coordinates VLDL assembly and secretion regulated by non-canonical mTOR signaling. Targeting the pathway efficiently suppresses liver steatosis.

Timeline

  1. Study published online in Nature Communications (doi:10.1038/s41467-026-79397-6)

  2. nature.com

    Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH

How do you feel about this?

0 Comments

    Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH – The Morning Science